Member Info for Lebus

But what’s the point of going to the expense and time involved in starting a phase 3 trial when the results of the Sprinter trial will be reported in a matter of a few weeks?

Excellent news

I’m expecting Proleukin to be a write off at some point. Sooner the better - get it out of the way I reckon.
Services side of the business is a different game altogether. Generates revenue that supports a dividend for investors( I’d happily forgo a dividend if the focus was on reducing debt). Clinigen has a niche product with still massive potential for growth.
At the rate Bank of America are increasing their stake in the business, Can’t be long before a bid

Bank of America still accumulating. The wolves are crouched in the bushes. Just hope it’s a costly pounce.

If I needed inhalation treatment my only concern would be that the device being used is 1.effective and 2. Easy to use. But each to their own

Inhaler maker Vectura facing backlash. Article in today’s Daily Telegraph

There is a statement relating to Vectura purchase on PMI’s website.

Refers to two key growth areas in their post nicotine strategy. The first is inhaled therapeutics. Reads and looks like they are picking up small businesses developing products delivered by inhalation.

£5 mil sold and around £4 mil buy with some big buy orders late doors. I anticipate a tick up tomorrow . I understand the concern about the need for speed. But look at the coronavirus rates worldwide. The WHO website is perhaps viewed as the most independent. This pandemic is a long way from being over. The delay in filling the phase 3 cohort is disappointing but no more than that.
I’m comfortable with my investment in this business.

“Profit warning hits shares in Pharma Services Company”. Article in Business Section. Reference to Elliott exploring future options. Also reference to a competitor having leapfrogged Erwinase to capture US market.

I think it’s safe to say that the market was not entirely happy with the financials. I’m staying with it but CEO needs to look over his shoulder. Elliott will have him in their sights. We all want a fair return on our investments - but the big players don’t just want, they demand.

Just to make you feel better - my break even is higher than yours even though I bought a bucket full at 4.80p. Ah well, the AIM is high risk and we all know that. I’m still comfortable holding. New Chairman on the way might add a spark and I say again - this business makes a profit every year and for share holders that’s our main expectation met

Has just waded in. Reckon you might get your £8 sooner than you expected Jatw. The vultures are circling but this is a profit making business with the potential for year on year growth. It won’t go cheaply

Agree totally just a case of premature disclosure by a medic

Yeh but the market needs clarity and that requires a RNS first thing tomorrow

The team will be working late in Southampton tonight. 7.00am RNS. Clarification needed pre market opening

And your analysis that leads you to this conclusion is?

Maybe they find the potential for a quicker profit elsewhere. Although Clinigen flags up a 12% reduction in anticipated profits this financial year, they still expect to show a profit of around £115 mil. This is a long way from being a failing Business. If you believe that COVID will at some point be under control, which will in turn allow societies and hospitals to return to near normal functioning, you will believe that this business retains the potential to resume year on year growth. A 30% reduction in valuation so far, on the back of this projected fall of 12% profit this year is in my view an extreme market response. Just a personal view

Albeit one of the few AIM listed businesses that pay any sort of dividend. This is a profit making business that has shown growth year on year. The suspension of Oncology trials in particular explains the adjusted forecast. It is an unfortunate but unavoidable consequence of this pandemic, and it’s impact on medical services world wide.

Profits will start to rise again as and when hospitals shift focus from COVID to more generic medical needs, and research programmes resume. In the meantime I’m staying fully invested

Well, a Proleukin update at last, albeit not the one we were hoping for. Business recovery tightly linked to Pandemic restrictions. Not gonna be a quick fix but I remain confident in Clinigen’s long term prospects

Further correction required. Motley Fool should be retitled Motley Idiot